Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Charles River Laboratories International has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Charles River Laboratories International's Interest Coverage for the quarter that ended in Jun. 2026 was 3.95.
Charles River Laboratories International's debt to revenue ratio for the quarter that ended in Jun. 2026 was 0.75.
As of today, Charles River Laboratories International's Altman Z-Score is 2.54.
Charles River Laboratories International (NYSE:CRL) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
Charles River Laboratories International has the Financial Strength Rank of 5.
Charles River Laboratories International Financial Strength Related Terms
CRL vs RVTY, ICLR, QGEN: Financial Strength Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International Financial Strength vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Financial Strength distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's Financial Strength falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Charles River Laboratories International has a Z-score of 2.54, indicating it is in Grey Zones. This implies that Charles River Laboratories International is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.
Warning Sign:
Altman Z-score of 2.54 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (CRL) has a Financial Strength of 5 as of Jun. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Charles River Laboratories International and its competitors. This is near median its historical median of 5.00. Over the past decade, Charles River Laboratories International's Financial Strength has ranged from 5.00 to 6.00.
Is Charles River Laboratories International's Financial Strength too high?
Charles River Laboratories International's current Financial Strength of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 6.00. Overall, Charles River Laboratories International has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Financial Strength compare to RVTY and ICLR?
Charles River Laboratories International's Financial Strength of 5 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Charles River Laboratories International's own Financial Strength has ranged from 5.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Medical Diagnostics & Research company?
A good Financial Strength depends on the Medical Diagnostics & Research industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current Financial Strength is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is $194.36, compared to a current price of $280.05 — trading 44.1% above its estimated fair value. The current Financial Strength is 5, which is near median its 10-year median of 5.00. Charles River Laboratories International's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current Financial Strength is 5 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $280.05 is trading 44.1% above its estimated GF Value™ of $194.36.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for CRL:
Financial Strength: 5 (near median its 10-year median of 5.00)
GF Value™: $194.36 vs. price of $280.05 (44.1% above fair value)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
74GF Score
Get the complete analysis for CRL
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
